Form 8-K - Current report:
SEC Accession No. 0001104659-25-093144
Filing Date
2025-09-25
Accepted
2025-09-25 08:23:11
Documents
14
Period of Report
2025-09-22
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2526892d1_8k.htm   iXBRL 8-K 24702
2 EXHIBIT 99.1 tm2526892d1_ex99-1.htm EX-99.1 11868
6 GRAPHIC tm2526892d1_ex99-1img01.jpg GRAPHIC 4764
  Complete submission text file 0001104659-25-093144.txt   213196

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nvct-20250922.xsd EX-101.SCH 3014
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nvct-20250922_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nvct-20250922_pre.xml EX-101.PRE 22358
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2526892d1_8k_htm.xml XML 3652
Mailing Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024
Business Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024 360-837-7232
Nuvectis Pharma, Inc. (Filer) CIK: 0001875558 (see all company filings)

EIN.: 862405608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41264 | Film No.: 251340266
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)